Ankylosing Spondylitis Treatment Market size to Reach USD 10.93 Billion by 2031, Driven by Biologics Adoption

The ankylosing spondylitis treatment market is projected to reach USD 10.93 billion by 2031, driven by broader biologics adoption, according to Mordor Intelligence. The forecast puts the 2026 market at USD 7.67 billion and an implied compound annual growth rate of 7.32% through 2031. Growth is supported by earlier and more accurate diagnosis of axial spondyloarthritis, aided by MRI and AI imaging, plus better reimbursement policies across developed and emerging markets. Biologics and biosimilars remain dominant, while oral JAK inhibitors gain traction as convenient options. Pricing competition and expanding healthcare access, especially in Asia Pacific, are fueling expansion.